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Abstract
Background: Bipolar disorder is a chronic and disabling psychiatric condition, characterised by recurrent episodes
of mania, hypomania and depression. It places a heavy burden on sufferers and families, with high societal and
healthcare costs. Many service users with a diagnosis of bipolar disorder also experience prominent psychotic
symptoms, with differential diagnoses of schizoaffective disorder, and relapses characterised by repeated manic
psychotic episodes and grandiosity. Such presentations require specific adaptations to standard bipolar disorder
interventions in order to address their psychosis, alongside mood regulation, with a particular emphasis on
impulsivity, irritability, disinhibition and elation. The Balancing ACT study aims to evaluate an innovative group
intervention combining Acceptance and Commitment Therapy and psychoeducation approaches (ACT/PE) with
individuals experiencing bipolar disorder and/or symptoms within community psychosis services.
Methods: The Balancing ACT study is a randomised controlled trial comparing Balancing ACT groups (ACT/PE)
plus routine care to routine care alone. Balancing ACT (ACT/PE) comprises ten group sessions, each lasting 2
hours, delivered weekly. The primary outcome is psychological wellbeing; secondary outcomes are mental health
relapses (measured by service use averages for the 12 months pre baseline and 3 months post baseline). We will also
measure mood, distress, recovery and psychological change processes. Participants will be randomised in a 1:1
ratio, after baseline assessment. Outcomes will be assessed by trained assessors blind to treatment condition at 0,
10 and 14 weeks. Recruitment began in April 2017 and is on-going until the end of October 2017.
Discussion: The Balancing ACT study will contribute to the currently limited evidence base for psychological
interventions for people experiencing bipolar disorder and/or symptoms in the context of community psychosis services.
Trial registration: ISRCTN73327972. Registered on 27 March 2017. Balancing ACT: evaluating the effectiveness of
psychoeducation and Acceptance and Commitment Therapy (ACT) groups for people with bipolar disorder.
Keywords: Bipolar disorder, Community mental health, Acceptance and Commitment Therapy (ACT), Psychosis,
Psychoeducation
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Background
Bipolar disorder is a chronic and disabling psychiatric
condition, characterised by recurrent episodes of mania,
hypomania and depression. It places a heavy burden on
sufferers and families, and has high societal and health-
care costs [1, 2]. An estimated 2 to 6% of the general
population in the UK meet the criteria for bipolar dis-
order, costing £5.2 billion annually in healthcare and lost
employment [3]. Many of the service users with a diag-
nosis of bipolar disorder also experience prominent
psychotic symptoms, with differential diagnoses of schi-
zoaffective disorder, and relapses characterised by re-
peated manic psychotic episodes and grandiosity. Such
presentations require specific adaptations to standard
psychological interventions for bipolar disorder in order
to address psychosis, alongside mood regulation, with a
particular emphasis on impulsivity, irritability, disinhib-
ition and elation [2].
The main treatment offered for bipolar disorder is
medication [2]. Despite this, many individuals continue
to experience residual symptoms, even when they are
fully concordant with medication, with rates of relapse
of between 40 and 60% [2, 4, 5]. Psychological therapies
were previously thought to add little to the treatment of
severe mental illness. However, psychological interven-
tions for people with psychosis are now firmly estab-
lished as clinical and cost-effective interventions, and,
although the move away from a predominantly medical
approach has been more recent for bipolar disorder,
there is increasing evidence that patients benefit from
high-quality psychological therapies, with clinical and
cost effects, as well as improving the quality of life of
service users and their families [6]. The National Insti-
tute for Health and Care Excellence [2] guidelines rec-
ommend up to 16 sessions of individual cognitive
behaviour therapy (CBT) including psychoeducation and
self-management/relapse prevention for bipolar disorder
and the same duration of intervention for people with
psychosis, incorporating self-monitoring, coping strat-
egies, distress-reduction and improving functioning.
Family Interventions (FI) and psychosocial/vocational
support are also recommended for both bipolar disorder
and psychosis.
A principal goal of psychoeducation for bipolar dis-
order is to provide accurate and reliable information, as
well as teaching early recognition and self-management
skills and facilitating service users to make informed de-
cisions about the management of their own mental
healthcare within the context of a collaborative working
relationship with their clinical team [7]. Psychoeducation
is usually facilitated in a group format and has also been
found to be helpful for family members and caregivers
of people with bipolar disorder, by reducing relapses and
increasing time spent well [7, 8].
Psychoeducation for service users with bipolar disorder
with mania and psychosis symptoms requires accurate
and detailed information about psychosis, recovery, and a
particular focus on symptoms of elevated mood and gran-
diosity. Traditional approaches to psychoeducation (e.g.
teaching people about the medical nature of their condi-
tion) alone for people with psychosis have been found to
be ineffective [9]. This could possibly be due to the diffi-
culty of establishing a shared understanding between the
service user and the clinical team in the context of differ-
ing levels of insight. Psychoeducation for this group must
accommodate these specific engagement issues to develop
individually tailored, validating and normalising under-
standings that do not inadvertently discredit personally
valued unusual experiences and beliefs. Psychoeducational
material of this kind has yet to be formally evaluated.
Acceptance and Commitment Therapy (ACT) is an
emerging psychological intervention which facilitates
self-management and acceptance of difficulties, and pro-
motes a focus on valued personal goals, in the face of
adversity [10]. ACT also promotes social inclusion by
shifting the service user’s focus from symptom control
to connecting with personal values and participating in
life. The central tenets of ACT, and its empowering, equit-
able, open and collaborative therapeutic stance, therefore
fit it well to a recovery ethos. Unlike many psychological
interventions, ACT relies on a philosophy which can be
readily trained, and a recent pilot study by our group in
South London and Maudsley NHS Foundation Trust,
funded by the Maudsley Charity, demonstrated that
co-facilitators could learn to deliver ACT by co-facilitating
groups over a 4-week course of therapy (Jolley S, Johns L,
O’Donoghue E, Oliver J, Khondoker M, Byrne M, Butler
L, De Rosa C, Sim F, Morris EM: A randomised controlled
trial of group acceptance and commitment therapy for pa-
tients and caregivers in psychosis services, Submitted).
ACT has shown good preliminary evidence of effect-
iveness for people with psychosis [11, 12] and ACT trials
have contributed to the recommendations of the NICE
guidance [13]. ACT has recently been piloted for people
with bipolar disorder who experience co-existing anxiety
and found to be effective [14]. However, group ACT and
psychoeducation interventions for people with bipolar
disorder have not yet been evaluated in a randomised
controlled trial (RCT). ACT’s transdiagnostic nature fits
well with mood instability alongside psychotic symptoms:
ACT aims to target transdiagnostic processes, and recent
studies indicate the potential effectiveness of ACT across a
broad spectrum of severe mental health conditions, in-
cluding mood instability and psychotic symptoms [11, 12].
ACT frames values, in particular, as remaining relatively
constant throughout a person’s life: mood episodes and
other problematic symptoms lead to the person losing
touch with their values, rather than fundamentally
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changing them. During depressive, hypomanic and manic
episodes, it is common for people to engage in activities
that are contrary to their normal values and/or to drop
activities that are in line with such values [15]. Such
changes may be driven, maintained and amplified by
cognitive distortions, including mood-consistent altered
perceptions of the future [15, 16], as well as experiential
avoidance of painful emotions, and reduced meta-cognitive
awareness. An explicit focus on values aims to help people
stay in touch with said values during prodromal mood
states, and thus remain engaged with ‘value-driven action’,
helping prevent escalation into mania or descent into
depression.
The values component of ACT helps people to get in
touch with chosen life directions, which will be present
regardless of an individual’s mood state; values provide a
source of reinforcement and goal-directed activity inde-
pendent of mood, as well as having elements that are
recovery-consistent. Accordingly, recent studies indicate
the potential for effectiveness across a broad spectrum
of severe mental health conditions [11, 12].
Study aims
We plan to carry out a pilot RCT to test out the poten-
tial feasibility and clinical and cost-effectiveness of our
Balancing ACT groups incorporating ACT and psy-
choeducation (ACT/PE), as an adjunct to routine care
(treatment as usual, TAU), in improving psychological
wellbeing in adults (aged 18 years or over) with a diag-
nosis of bipolar disorder and/or bipolar symptoms in
community psychosis services. The Balancing ACT
(ACT/PE) intervention plus TAU condition will be
compared to TAU alone. Service users allocated to
TAU will be offered the Balancing ACT intervention
after completing the final study assessment.
The specific research questions to be addressed are:
1) Are primary and secondary clinical outcomes for
people with bipolar disorder and/or bipolar
symptoms in psychosis community services
potentially improved by the addition of ACT/PE
groups? If so, to what extent, and with what likely
variability in effect size?
2) Do the ACT/PE groups have a potential positive
impact on mood, distress, recovery and
psychological processes of change?
3) Is the ACT/PE intervention potentially cost-effective?
4) Is it feasible to add ACT/PE approaches to bipolar
disorder psychological treatments?
Methods
Participants and setting
We aim to recruit 36 adults aged 18 years or over, pre-
senting to the Promoting Recovery Service Community
Mental Health Teams of the Psychosis Clinical Academic
Group of the South London and Maudsley NHS
Foundation Trust (SLaM) within King’s Health Partners.
Ten teams, from the inner-London boroughs of Lambeth
and Southwark are participating. The sample will include
service users with diagnoses of bipolar affective disorder
and schizoaffective disorder. A recent local audit showed
that of 1344 adults currently treated in SLaM with a diag-
nosis of bipolar disorder, more than half (N = 823) are be-
ing treated within psychosis services, with around 200 in
each borough (13–20% of the caseload). As such, we ex-
pect recruitment to be reasonably straightforward.
The proposed sample size, while representing only a
small proportion of the caseload, is in line with recom-
mendations for the number of participants required to
estimate variance in outcomes and is, therefore, appro-
priate for an early stage feasibility study. (24 to 50 par-
ticipants [17, 18]). The feasibility study is designed to
feed into a second larger pilot study, which will benefit
from feedback received in the current study, and allow
consideration of the representativeness of the study
sample.
Inclusion and exclusion criteria
Inclusion criteria are: presenting to, and being treated
under, Lambeth or Southwark Promoting Recovery Ser-
vices (the services see working age adults, aged 18 years
or over); diagnosis of bipolar disorder and/or bipolar
symptoms; being available for the study duration; suffi-
cient English language ability to be able to complete as-
sessment measures and participate in therapy, without
interpreter support (as this cannot feasibly be provided
in a group context). Exclusion criteria are: inability to re-
main in a group setting, attend and understand and
interact for up to 2 h; considered by the treating team to
lack capacity to consent. This will mean that people with
acute extremes of mood state are unlikely to meet the
inclusion criteria, although an extreme mood state will
not be an exclusion criterion in itself.
Study design
Balancing ACT is an RCT with random allocation to
one of two arms, comparing our active intervention
(ACT/PE + TAU) to routine care alone (TAU). TAU will
be delivered without interference in both conditions and
includes care coordination, medication, and practical/
emotional support for the individual. We will record
what is delivered as TAU. Assessments will take place at
baseline (0 weeks), 10 weeks (post therapy) and 14 weeks
(post-booster session). After 14 weeks, TAU participants
will be offered the intervention. Trained research workers
will complete assessments with participants. Baseline
assessments will be carried out prior to randomisation;
10- and 14-week assessments will be arranged by the trial
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research worker, but carried out by a different assessor,
who will be blind to treatment allocation. Service mea-
sures [19] will be completed for the 12-month period be-
fore baseline and 3 months after the final baseline
assessment. The study design is illustrated in Fig. 1.
Procedure
Recruitment
We will recruit directly from Promoting Recovery
Services in Lambeth and Southwark boroughs. Adults
presenting with bipolar disorder and/or symptoms will
be invited by their team to find out more about the
study, and, if agreeing, will be contacted by the Balan-
cing ACT study researcher. Telephone conversations
and meetings will take place as needed to discuss the
study. Participants will be provided with an information
sheet and consent form. If an individual consents to par-
ticipate, they will be offered a baseline assessment and
will be randomised only following completion of this.
Ethical approval
The study has been reviewed and given a favourable
opinion by the London-Surrey Borders National Research
Ethics Committee (REC Reference: 17/LO/04/45).
Intervention
The ACT/PE intervention will consist of ten groups, each
running over ten consecutive weeks, followed by a booster
session, 4 weeks later. Each group session will last for 2 h.
The intervention will be delivered in addition to routine
care (specialist care coordination, medication, practical and
emotional support), and will be compared to routine care
alone (TAU). After the 14-week assessment, individuals in
the routine care condition will be offered the intervention.
The ACT/PE intervention will focus on psychoeduca-
tion approaches to understanding bipolar and mood disor-
ders. Each session will focus on a different issue pertinent
to bipolar disorder; including, mania, stress, sleep, depres-
sion, medication, communicating with friends and family,
and relapse prevention. Each session will introduce ACT
skills as a different way of responding to symptoms of bi-
polar disorder. The Balancing ACT groups are designed to
be interactive with experiential exercises throughout and a
commitment to work towards a valued goal, and the prac-
tice mindfulness exercises in between sessions.
We acknowledge that 14 weeks is a relatively short
timeframe to assess change. For the pragmatic purposes
of this study, because we are interested in the potential
helpfulness of the intervention, rather than the longevity
of the effects, we consider this time period appropriate.
Fig. 1 Balancing ACT: evaluating the effectiveness of psychoeducation and Acceptance and Commitment Therapy (ACT) groups for people with
bipolar disorder: study protocol for a pilot randomised controlled trial. Study design
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ACT has been shown to achieve change in brief inter-
ventions: previous studies from our research group [20]
have shown significant change in 12 weeks during ACT
interventions with clients with psychosis. This is longer
than ACT interventions would normally be, but con-
sistent with psychoeducation groups for people with
bipolar disorder [6–8]. A future study can address
maintenance of effects over time.
Therapists
We will train and supervise therapists within the service
to deliver the intervention. Therapists will be trained to
competence in delivery of the manualised intervention,
will co-work with a member of the study team, and will
be closely supervised by the trial coordinator.
Measures
Outcome and timeline
Following informed consent from each participant, all
outcomes will be assessed by a trained study researcher.
Demographic/clinical characteristics (age, gender, ethni-
city, diagnosis) will be assessed at baseline. Outcomes
will be assessed at baseline (0 weeks), then at 10 weeks
and 14 weeks post randomisation (Table 1).
Trial and intervention feasibility parameters
The feasibility of the trial will be assessed using recruit-
ment, randomisation and attrition rates. Intervention
feasibility will be evaluated by treatment adherence and
patient satisfaction.
Primary outcome
The proposed primary outcome will be psychological
wellbeing assessed by the Brief Quality of Life in Bipolar
Disorder (Brief QoL.BD) [21]. The Brief QoL.BD is well
validated and routinely to assess quality of life in people
with bipolar disorder [22, 23].
Secondary outcomes
The proposed secondary outcome of service use will be
assessed from the medical records for the 12 months
preceding entry to the study and the 3 months during
the trial. We will calculate the number of admissions to
hospital and contacts with the crisis/home treatment
team as well as days under each of these services as an
average per month. This is an indication of the severity
of the presentation and the cost to the service of care.
Other clinical outcomes
Mood [24], distress recovery [25, 26] and psychological-
change processes [27–29] will also be assessed at 0, 10 and
14 weeks. Mood will be assessed sessionally using an
un-numbered Likert scale measuring 12 cm, rated from
depression/down at one extreme, through normal at 6 cm
to manic/high at the other extreme. We also aim to collect
qualitative feedback from participants on their experiences
of the Balancing ACT group and its impact on their
recovery.
Service use and costs
We will approximate costs by counting average service
use/month for the 12 months preceding randomisation
[19], and the 3 months following randomisation. Service
use variables will include number of psychiatric inpatient
admissions, days as an inpatient, number of crisis team
contacts, and days under the crisis team.
Sample size
Resources allow us to recruit 36 participants to our study.
Although this number is relatively small it will allow us to
gain measures of trial feasibility (such as recruitment
rates) and an estimation of the variance following dropout.
Sample size estimates for effect size (ES) calculation may
start from a total N of 24 [17]. However, ES calculated
from small samples are sensitive to inflation [18] and we
will take this inflation factor into account when conduct-
ing a power analysis for a larger trial.
Table 1 Balancing ACT: evaluating the effectiveness of
psychoeducation and Acceptance and Commitment Therapy
(ACT) groups for people with bipolar disorder: Study protocol
for a pilot randomised controlled trial. List of measures
Completed at:
Service user measures
Brief Quality of Life in Bipolar Disorder
(Brief QoL.BD: Michalak and Murray, 2009) [21]
1, 2, 3
Clinical Outcomes in Routine Evaluation
Measure (CORE-10; Barkham et al., 2008) [25]
1, 2, 3
Valuing Questionnaire (VQ8; Smout et al., 2014) [27] 1, 2, 3
Acceptance and Action Questionnaire-II
(AAQ-II; Bond et al., 2011) [28]
1, 2, 3
Southampton Mindfulness Questionnaire
(SMQ; Chadwick et al., 2008) [29]
1, 2, 3
Bipolar Recovery Questionnaire
(BRQ; Jones et al., 2013) [26]
1, 2, 3
Internal States Scale (ISS; Bauer, 1991) [24] 1, 2, 3
Researcher-rated measure
Client Service Receipt Inventory
(CSRI; Beecham and Knapp, 2001) [19]
for the 12 months preceding and 3 months
following baseline
1, 3
Service use (average/month) in preceding
12 months and following 3 months
from baseline
Sessional measures
Brief Quality of Life in Bipolar Disorder
(Brief QoL.BD: Michalak and Murray, 2009) [21]
Sessional
Key: Completed at: 1 = baseline (0 weeks), 2 = post therapy (10 weeks); 3 =
post follow-up (14 weeks)
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Randomisation
Randomisation will be carried out after consent to par-
ticipate in the trial has been given and the baseline as-
sessment has been carried out. Participants will be
randomised through an independent web-based service
provided by UKCRG registered King’s Clinical Trials
Unit (Reg. No. 053). The randomisation procedure will
employ methods to maintain pre-randomisation alloca-
tion concealment. We will stratify by site for logistical
reasons, so that treatment cases are equitably allocated
across sites.
Blinding procedure
We will not be able to blind participants to treatment
group. Similarly, the therapists cannot be blind to alloca-
tion as they will deliver the intervention. However, the
research workers completing the outcome measure-
ments will be blinded to treatment allocation. Should
they be accidentally unblinded during the assessment,
we will record which outcomes were completed blind
and allocate a new assessor for any subsequent assess-
ments. Post-randomisation assessors will work separately
from the research and clinical teams to minimise the
likelihood of unblinding. We will report any instances
of unblinding in subsequent publications. The end of
the trial will be defined as the last follow-up at
14 weeks. The trial statistician will also be blinded to
treatment group for the analysis of clinical and func-
tional outcomes.
Data monitoring
Based on pre-pilot studies we do not anticipate risks to
participant safety as a direct result of the study. We will
not be conducting any interim data analysis and will not
convene a separate Data Monitoring Committee. The
trial may be prematurely discontinued by the sponsor,
REC or chief investigator (with the agreement of the
sponsor and the REC) on the basis of new safety infor-
mation or for other reasons given by the sponsor or the
REC. As the study is a small pilot, we will not convene a
Trial Steering Committee. The study will be subject to
the standard local and national governance frameworks
of the sponsor, the Promoting Recovery Services and re-
search coordination, the clinical research network and
the REC.
Data management
We will use paper assessment packs and enter data into
electronic databases which include: (1) baseline demo-
graphics, (2) repeated clinical measures, (3) sessional
therapy measures and (4) therapy delivery and adher-
ence. Outcome assessments will be carried out by re-
searchers who do not have access to therapy or feedback
data. Data will be checked and cleaned against original
paper copies and a final database returned to the statisti-
cian, who will combine with allocation data for analysis.
Patient data will be pseudonymised for the duration of
the study and fully anonymised thereafter. Fully identifi-
able personal details will be kept on paper in a locked
filing cabinet in a locked or occupied office; on secure
NHS computers; and encrypted on password-protected
computers. All trial data will be stored in line with the
Data Protection Act [30].
The allocation database will be accessible only to the
study randomiser (who will not conduct post-baseline
assessments) and the trial statistician until the study is
completed.
Safety monitoring and adverse event reporting
We do not anticipate safety concerns arising as a direct
result of the therapy, which is usually perceived as help-
ful by service users. However, we will monitor adverse
events, defined as any deterioration in psychosocial
functioning, irrespective of severity, carefully as one of
our outcomes. All adverse events will be reported to the
clinical team to ensure adequate care, and will be docu-
mented by the study team. Events considered by the par-
ticipant, clinical service or research team to be
unexpected and related to the study will be reviewed for
seriousness. Serious adverse events that are related to
the trial will be reported to the trial sponsor and the
REC within 15 days.
Statistical analysis
In accordance with the Consolidated Standards of
Reporting Trials (CONSORT) principles, we will report
all participant flow in the study. The aim of the analysis
will be to describe the feasibility and acceptability of
the trial ACT/PE intervention and estimate effect sizes
for group differences in attitude, adherence, clinical
and quality of life outcomes. Binary outcomes will be
analysed using logistic regression, chi-square or Fisher’s
exact test if expected values were small. Continuous
outcome scores will be analysed using analysis of co-
variance (ANCOVA) models in which the mean group
difference will be adjusted for baseline outcome scores.
Clustering for patients within therapy groups will be
accounted a random effect for cluster in the ANCOVA
models. Effect sizes will be derived from standardised
regression coefficients in which treatment group differ-
ences, adjusted for outcomes scores at baseline, will be
divided by the standard deviation of the outcomes. Fol-
lowing Cohen’s guidelines, effect sizes will be treated as
small (ES = 0.2), moderate (ES = 0.5) or large (ES = 0.8).
As a pilot study, the sample size may not give suffi-
cient power to reject null hypotheses; however, we will
derive inferential statistics on the intention-to-treat
principle. As the sample size is small and regression
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assumptions may not be met and we will use robust
methods, such as bootstrap resampling, to derive stand-
ard errors and bias-corrected accelerated confidence in-
tervals. Missing data will be described per outcome and
if possible mechanisms driving missingness accounted
for in the statistical model under the assumption that
data is missing at random and with sensitivity analyses.
All statistical tests will be two-sided and confidence
interval level set at 95%. STATA 14.1 (StataCorp, College
Station, TX, USA) will be used to analyse the data.
Discussion
We have adhered to Standard Protocol Items: Recom-
mendations for Interventional Trials (SPIRIT) [31, 32]
guidance in devising and reporting our protocol
(Fig. 2; SPIRIT Checklist with information sheets and
consent forms for participants are included as an
Additional file 1). The trial is funded until the end of
July 2018. The study will be the first study of its kind
examining ACT and psychoeducation groups for
people with bipolar disorder and/or symptoms. Should
the intervention prove feasible, acceptable and potentially
helpful cost-effective addition to routine care, we will
apply for funding for a larger-scale evaluation. If outcomes
suggest that the intervention does not show promise in
terms of potential clinical improvement, we will continue
to refine the intervention, based on participant feedback,
further consultation, and our process measures, before
attempting a further pilot. Findings will be limited by the
pilot nature of the study, including the small sample size,
location in a single service and opportunistic recruitment
strategy. The therapy will be compared to treatment as
usual and not to an alternative psychological intervention,
so any effects found may be non-specific. We are not
assessing longevity of effects in this study: further research
will be required to ascertain longer-term outcomes.
We plan to disseminate our findings via local aca-
demic and clinical networks, through conference pres-
entation and publication. Authorship will be restricted
to those making a substantial contribution to the spe-
cific publication.
Status
Participants began to enter the trial in April 2017. The
first participant was randomised on 10 May 2017. Recruit-
ment will continue until end of October 2017. We antici-
pate that final primary outcome data will be collected by
the end of February 2018.
Additional file
Additional file 1: Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 Checklist: recommended items to
address in a clinical trial protocol and related documents*. (DOC 121 kb)
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